On basis of these phase clinical trials, FDA granted atezolizumab “a breakthrough therapy” designation in February 2015 for the treatment of PDL1‐positive NSCLC Patients during or post after standard treatments.It is the first PD‐L1 inhibitor approved for use in patients with NSCLC who are on platinum‐doublet chemotherapy or appropriate targeted therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.